ArticleJournal of autoimmunity2018
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Open access · hybridAbstract read
In one paragraph
Article in Journal of autoimmunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 1 synthesis or guideline pooled it, 147 citations in OpenAlex.
- A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.EBioMedicine · 2023Pooled it
- Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.ImmunoHorizons · 2025Trial
- Cytokine-independent activation of STAT5 promotes the persistence and function of CD4Molecular therapy. Advances · 2026Article
- Review
- Regulatory T cell induction strategies and applications in the treatment of immune and non-immune diseases.Signal transduction and targeted therapy · 2026Review
- Localized immunomodulation with cytokine-producing cells to mitigate foreign body responses in rodents and a nonhuman primate.Science advances · 2026Article
- Advancement of humanized mice and leading applications in immunological disease models.Inflammation and regeneration · 2026Review
- Taming immune responses to AAV gene therapy by programmed in vivo Treg expansion.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Article
- A modular platform for Sterically Masked Activated Cytokines (SMACks).Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Miniaturized IL-2/anti-IL-2 immunocytokines selectively activate and support theFrontiers in immunology · 2026Article
- Thirty years in, regulatory T cells are ready for medicine.Frontiers in immunology · 2026Review
- Regulatory T cells and peripheral immune tolerance: key mechanisms and therapeutic strategies for cardiovascular diseases.Frontiers in immunology · 2026Review
- Article
- FOXP3 Stability-Adaptation Paradox: Reshaping Treg-Based Therapies for Intestinal Diseases.International journal of biological sciences · 2026Review
- Predictive markers for the efficacy of CAR T-cell therapy: the interplay between CAR T-cell fitness and systemic immunity.Blood advances · 2025Review
- Dual targeting OX40 and IL-2 receptor enhances antitumor activity through tumor-infiltrating Treg depletion and CD8Journal for immunotherapy of cancer · 2025Article
- Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity.Cell reports. Medicine · 2025Article
- Regulatory T cell therapy in autoimmune liver disease and transplantation.JHEP reports : innovation in hepatology · 2025Review
- Regulating IL-2 Immune Signaling Function Via A Core Allosteric Structural Network.Journal of molecular biology · 2025Article
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Laurence B PetersonRoche Innovation Center Basel, Roche Pharma Research & Early Development (pRED), Grenzacherstrasse 124, 4070, Basel, Switzerland; JDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, CB2 OXY, UK.
Charles J M BellJDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, CB2 OXY, UK.
Sarah K HowlettJDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, CB2 OXY, UK.
Marcin L PekalskiJDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; JDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, CB2 OXY, UK.
Kevin BradyRoche Innovation Center Basel, Roche Pharma Research & Early Development (pRED), Grenzacherstrasse 124, 4070, Basel, Switzerland.
Heather HintonRoche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
Denise SauterRoche Innovation Center Basel, Roche Pharma Research & Early Development (pRED), Grenzacherstrasse 124, 4070, Basel, Switzerland.
John A ToddJDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; JDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, CB2 OXY, UK.
Pablo UmanaRoche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
Oliver AstRoche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
Inja WaldhauerRoche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
Anne Freimoser-GrundschoberRoche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
Ekkehard MoessnerRoche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
Christian KleinRoche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
Ralf J HosseRoche Innovation Center Zurich, Roche Pharma Research & Early Development (pRED), Wagistrasse 10, 8952, Schlieren, Switzerland.
Linda S WickerJDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; JDRF/Wellcome Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Research, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, CB2 OXY, UK. Electronic address: lswicker@well.ox.ac.uk.
Roche (Switzerland) · CHCentre for Human Genetics · GBUniversity of Cambridge · GB
Funding
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1MDepartment of HealthWellcome Trust 096388Wellcome Trust 107212
Abstract
Susceptibility to multiple autoimmune diseases is associated with common gene polymorphisms influencing IL-2 signaling and T
Indexed as
AnimalsAutoimmune DiseasesBinding SitesCD8-Positive T-LymphocytesCell ProliferationCTLA-4 AntigenDisease Models, AnimalDNA MethylationEpigenesis, GeneticForkhead Transcription FactorsHumansImmunoglobulin GImmunotherapyInterleukin-2Interleukin-2 Receptor beta SubunitLymphocyte ActivationCTLA-4 AntigenCTLA4 protein, humanForkhead Transcription FactorsFOXP3 protein, humanIL2 protein, humanImmunoglobulin GInterleukin-2Interleukin-2 Receptor beta SubunitLymphotoxin-alphaProtein IsoformsRecombinant Fusion ProteinsSTAT5 Transcription FactorAutoimmunityCytokine therapyIL-2 muteinImmunotherapyT(reg) expansion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.